NCT07780097

Brief Summary

The primary objective of this study is to evaluate the ability of TRTME to increase initiation of MOUD outpatient treatment and MOUD knowledge in hospitalized patients with OUD deemed to be good candidates for MOUD by the UCMC Addiction Consult Team (ACT). The secondary objective is to evaluate the ability of TRTME to decrease stigma and increase drug self-efficacy.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
30

participants targeted

Target at below P25 for not_applicable

Timeline
6mo left

Started Aug 2026

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress10%
Aug 2026Feb 2027

First Submitted

Initial submission to the registry

August 11, 2026

Completed
1 day until next milestone

Study Start

First participant enrolled

August 12, 2026

Completed
9 days until next milestone

First Posted

Study publicly available on registry

August 21, 2026

Completed
6 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 28, 2027

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

February 28, 2027

Last Updated

August 21, 2026

Status Verified

August 1, 2026

Enrollment Period

7 months

First QC Date

August 11, 2026

Last Update Submit

August 18, 2026

Conditions

Opioid Use DisorderOpioid Use Disorder, ModerateOpioid Use Disorder, Severe

Keywords

opioidOpioid Use DisorderMOUDbuprenorphinemethadone

Outcome Measures

Primary Outcomes (1)

  • Outpatient MOUD initiation

    The primary outcome is verified enrollment in outpatient MOUD within 30 days post-discharge. Participants will be asked about their enrollment in MOUD approximately 30 days after their discharge from the hospital. Participants reporting having enrolled in treatment will be asked to provide a release of information for the treatment program to verify date of treatment enrollment.

    30 days

Secondary Outcomes (4)

  • MOUD knowledge score

    Immediately after the intervention

  • MOUD Stigma

    Immediately after the intervention

  • Drug Self-efficacy

    Immediately after the intervention

  • Opioid-overdose knowledge score

    Immediately after the intervention

Study Arms (2)

Control

NO INTERVENTION

Control participants will be offered two SAMHSA handouts: 1) "Opioid Overdose Prevention Toolkit: Safety Advice for Patients and Family Members"; and 2) "Medication-Assisted Treatment for Opioid Addiction: Facts for Families and Friends". These handouts can be offered as physical copies or electronically.

TRTME

EXPERIMENTAL

TRTME participants will be offered a 15-minute intervention in which a trained research staff member reviews personal feedback reports with the recipient to provide information on: 1) the items missed on the knowledge assessment; and 2) their personal overdose risk factors. TRTME participants will also have the opportunity to view short videos from patients talking about their experiences with methadone or buprenorphine treatment.

Behavioral: TRTME

Interventions

TRTMEBEHAVIORAL

The TRTME intervention includes three elements that have all been previously studied by our research team: 1) brief, personally-tailored education to correct inaccurate, common misconceptions about MOUD and to address knowledge gaps about opioid-overdose; 2) with personally-tailored feedback on the individual's risk factors for experiencing an opioid-overdose; and 3) review of MOUD testimonial videos.

TRTME

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • years of age or older;
  • A good candidate for methadone or buprenorphine treatment according to a member of the UCMC Addiction Consult Team

You may not qualify if:

  • Have a current planned discharge to a nursing facility
  • be currently in jail, prison, or any inpatient overnight facility as required by court of law or have pending legal action with high probability of incarceration or court-mandated inpatient treatment
  • Unable to demonstrate adequate understanding of study procedures during the consent process

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University of Cincinnati Addiction Sciences Division

Cincinnati, Ohio, 45229, United States

RECRUITING

MeSH Terms

Conditions

Opioid-Related DisordersLymphoma, Follicular

Condition Hierarchy (Ancestors)

Narcotic-Related DisordersSubstance-Related DisordersChemically-Induced DisordersMental DisordersLymphoma, Non-HodgkinLymphomaNeoplasms by Histologic TypeNeoplasmsLymphoproliferative DisordersLymphatic DiseasesHemic and Lymphatic DiseasesImmunoproliferative DisordersImmune System Diseases

Study Officials

  • T. John Winhusen, PhD.

    University of Cincinnati

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Lindsay Bybee, MS

CONTACT

5135858282saskowld@uc.edu

Ben Kropp Kropp, MSLS

CONTACT

5135858287kroppbn@ucmail.uc.edu

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
HEALTH SERVICES RESEARCH
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
Professor; Vice Chair and Division Director of Addiction Sciences

Study Record Dates

First Submitted

August 11, 2026

First Posted

August 21, 2026

Study Start

August 12, 2026

Primary Completion (Estimated)

February 28, 2027

Study Completion (Estimated)

February 28, 2027

Last Updated

August 21, 2026

Record last verified: 2026-08

Locations

US(1)